Document d'orientation sur l'utilisation du vaccin monovalent inactivé contre la grippe pandémique A (H1N1) 2009

[Précédente] [Table des matières]

17.0  Références

1. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children – Californie du Sud, mars-avril 2009. MMWR 2009; 58:400-2.
2. Centers for Disease Control and Prevention. Outbreak of swine-origin influenza A (H1N1) virus infection – Mexique, mars-avril 2009. MMWR 2009; 58:467-70.
3. Agence de la santé publique du Canada. Rapport hebdomadaire Surveillance de l’influenza 5 juillet-11 juillet 2009 (Semaine 27). Voir : http://www.phac-aspc.gc.ca/fluwatch/08-09/w27_09/pdf/fw2009-27-fra.pdf 
4. Agence de la santé publique du Canada. Rapport hebdomadaire Surveillance de l’influenza Semaine 43 (25-31 octobre 2009). Voir : http://www.phac-aspc.gc.ca/fluwatch/09-10/w43_09/index-fra.php
5. European Centre for Disease Prevention and Control. ECDC Interim Risk Assessment – Pandemic H1N1 2009. 25 septembre 2009 Voir :  http://www.ecdc.europa.eu/en/healthtopics/
   Documents/0908_Influenza_AH1N1_Risk_Assessment.pdf
6. Agence de la santé publique du Canada. Données de surveillance non publiées.
7. Presanis AM, Lipsitch M, De Angelis D et al. The severity of pandemic H1N1 influenza in the United States. Avril-juillet 2009. PLoS Currents Influenza 25 septembre 2009 (révisé le 2 octobre 2009): RRN1042. Voir :  http://knol.google.com/k/anne-m-presanis/
   the-severity-of-pandemic-h1n1-influenza/agr0htar1u6r/16#
8. Centers for Disease Control and Prevention. Réunion du 29 juillet 2009 de l’ACIP. Fiore A. Novel influenza A (H1N1) Epidemiology update. Voir :  http://www.cdc.gov/vaccines/recs/ACIP/
   downloads/mtg-slides-jul09-flu/02-Flu-Fiore.pdf
9. Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 influenza virus infection in pregnancy in the USA. Lancet 2009; 374:451-8.
10. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther. Août 2009;9(8):1057-71.
11. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactivity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9. 
12. European Medicines Agency. CHMP Assessment Report for Pandemrix. Voir :  http://www.emea.europa.eu/humandocs/PDFs/
    EPAR/pandemrix/Pandemrix-H-832-PU-17-AR.pdf
13. Greenberg ME, Lai MH, HartelGF et al. Response after one dose of a monovalent 2009 Influenza A (H1N1) Vaccine – Preliminary Report. N Engl J Med 2009; 361 (affiché à  nejm.org le 10 septembre 2009).
14. Clark TW, Pareek M, Hoschler K et al. Trial of Influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine – preliminary report N Engl J Med 2009; 361 (affiché à  nejm.org le 10 septembre 2009).
15. US Department of Health and Human Services. Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults. HHS News. 11 septembre 2009. Voir :  http://www3.niaid.nih.gov/news/newsreleases/2009/H1N1TrialsResults.htm
16. Sanofi Pasteur. Sanofi Pasteur announces results of US clinical trials in adults following one dose of influenza A (H1N1) vaccine. Comm. de presse 14 oct. 2009. Voir :  http://www.sanofipasteur.com/sanofi-pasteur2/sp-media/SP_CORP/
    EN/54/947/H1N1 US TRIAL RESULTS 011009 ENG.pdf?siteCode=SP_CORP
17. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Early results: NIAID trial supports co-administration of 2009 H1N1 influenza vaccine and seasonal influenza vaccine. Bulletin du 9 octobre 2009. Voir :  http://www3.niaid.nih.gov/news/newsreleases/2009/H1N1plusSeasonalVax.htm
18. GlaxoSmithKline Canada. Arepanrix^MC H1N1 - Vaccin contre la grippe pandémique (H1N1) contenant l'adjuvant AS03. Feuillet de renseignements sur le produit, 2009. Voir :  http://www.hc-sc.gc.ca/dhp-mps/prodpharma/
    legislation/interimorders-arretesurgence/prodinfo-vaccin-fra.php
19. GlaxoSmithKline. Pandemic 2009 influenza update: Pandemrix™ data in an elderly population. Comm. de presse, 27 oct. 2009. Voir :  http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10119.htm
20. GlaxoSmithKline. Pandemic (H1N1) 2009 Influenza Update: Experience of GSK’s H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results. Comm. de presse 23 oct. 2009. Voir :  http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10116.htm
21. Jefferson T, Rivetti A, Harnden A et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 16 avril 2008, Numéro 2: CD004879.
22. Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28(7):563-571.
23. National Institute of Allergy and Infectious Diseases. Updated results: in youngest children a second dose of 2009 H1N1 vaccine elicits robust immune response. Bulletin, 2 nov. 2009. Voir :  http://www3.niaid.nih.gov/news/newsreleases/2009/interimpedsdata.htm
24. National Institute of Allergy and Infectious Diseases. Initial results show pregnant women mount strong immune result to one dose of 2009 H1N1 flu vaccine. Comm. de presse, 2 nov. 2009. Voir :  http://www3.niaid.nih.gov/news/newsreleases/2009/H1N1pregnantresults.htm
25. Centers for Disease Control and Prevention. Hospitalized patients with novel influenza A (H1N1) virus infection - Californie, avril-mai 2009. MMWR Morb Mortal Wkly Rep 2009. 22 mai; 58(19):536-41.
26. Centers for Disease Control and Prevention. Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, juin 2009. MMWR Morb Mortal Wkly Rep 17 juil. 2009; 58(27):749-52.
27. Comité consultatif national de l’immunisation. « Déclaration sur le vaccin antigrippal trivalent inactivé (VTI) pour la saison 2009-2010 ». Relevé des maladies transmissibles au Canada 2009, vol. 35, (ACS 6). Voir : http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acs-dcc-6/index-fra.php
28. Black SB, Shinefield HR, France EK et al. Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Amer J Perinatology 2004;6:333-9.
29. Schanzer DL, Langley JM, Tam TW. Influenza-attributed hospitalization rates among pregnant women in Canada 1994-2000. J Obstet Gynaecol Can 2007;29:622-9.
30. Tuyishime JD, De Wals P, Moutquin JM et al. Influenza-like illness during pregnancy: results from a study in the Eastern Townships, province of Quebec. J Obstet Gynaeocol Can 2003; 25:1020-5.
31. MacDonald NE, Riley LE, Steinhoff MC. Influenza immunization in pregnancy. Obstetrics and Gynecology. Obstet Gynecol Août 2009;114(2 Pt 1):365-8.
32. Skowronski DM, De Serres G. Is routine influenza immunization warranted in early pregnancy? Vaccine. 30 juillet 2009; 27(35):4754-70. Epub 16 avril 2009.
33. McNeil SA, Halperin B, MacDonald NE. Influenza in pregnancy: the case for prevention. Adv Exp Med Biol 2009; 634:161-83.
34. Mak TK, Mangtani P, Leese J et al. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 2008; 8:42-52.
35. Neuzil KM, Reed GW, Mitchel EF et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1997; 148:1094-8.
36. Dodds L, McNeil SA, Fell SB et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. JAMC. 2007; 176:463-8.
37. Hartert TV, Neuzil KM, Shintani AK et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol 2003; 189:1705-12.
38. Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal influenza immunization in mothers and infants. NEJM 2008; 359:1-10.
39. Negri E, Colombo C, Giordano L et al. Influenza vaccine in healthy children: a meta-analysis. Vaccine 2005; 23(22):2851-61.
40. Manzoli L, Schioppa F, Boccia A et al. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J 2007; 26(2):97-106.
41. Hayward AC, Harling R, Wetten S et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006; 333(7581):1241.
42. Potter J, Stott DJ, Roberts MA et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175(1):1-6.
43. Pearson ML, Bridges CB, Harper SA. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-2):1-16.
44. Carman WF, Elder AG, Wallace LA et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000; 355(9198):93-7.
45. Wilde JA, McMillan JA, Serwint J et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281(10):908-13.
46. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18(9):779-83.
47. GlaxoSmithKline Canada. Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (without Adjuvant). Feuillet de renseignements sur le produit, 2009. Voir :  http://www.hc-sc.gc.ca/dhp-mps/prodpharma/legislation/interimorders-arretesurgence/prodinfo-vaccin-na-fra.php
48. Organisation mondiale de la santé. WHO virtual consultation on the safety of adjuvanted influenza vaccines (3 juin 2009). Voir :  http://www.who.int/vaccine_research/InfluenzaMeeting/en/index.html
49. Rumke HC, Bayas J, de Juanes J et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-2388.
50. Carter NJ, Plosker. Prepandemic influenza vaccine H5N1 (Split Virion, Inactivated, Adjuvanted) (Prepandrix^TM). A review of its use as an active immunization against influenza A subtype H5N1 virus. Biodrugs 2008; 22(5) 279-292.
51. GlaxoSmithKline. Pandemic (H1N1) 2009 influenza update: results from second clinical trial of GSK’s H1N1 adjuvanted vaccine confirm immune response and tolerability. Comm. de presse, 16 oct. 2009. Voir :  http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10111.htm
52. Agence européenne des médicaments. Pandemrix™ – summary of product characteristics. Voir :
     http://www.emea.europa.eu/humandocs/PDFs/EPAR/pandemrix/
    D-H1N1%20single%20PDFs/SPC/emea-spc-h832pu17en.pdf
53. Lakemedelsverket. Sommaire des rapports sur des effets secondaires associés aux médicaments en Suède et mettant en cause Pandemrix. 29 oct. 2009. Voir :  http://www.lakemedelsverket.se/english/All-news/NYHETER---2009/
    Summary-of-the-information-published-on-the-MPA-website-Oct-29-2009-
    regarding-adverse-drug-reaction-reports-in-Sweden-with-Pandemrix--the
    -influenza-A-H1N1-vaccine/
54. Pellegrini M, Nicolay U, Lindert K et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine 2009; 27(49):6959-65. Epub 12 sept. 2009.
55. Langmuir AD, Bregman DJ, Kurland LT et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984; 119(6):841-79.
56. Institute of Medicine. Immunization Safety Review: Influenza Vaccines and Neurological Complications. Washington, DC: Institute of Medicine of the National Academies; 2008.
57. McLean M, Duclos P, Jacob P et al. Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology 1994; 5(4):443-8.
58. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366(9497):1653-66.
59. Sivadon-Tardy V, Orlikowski D, Porcher R et al. Guillain-Barré syndrome and influenza virus infection. Clin Infect Dis 2009; 48:48-56.
60. Juurlink DN, Stukel TA, Kwong J et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006; 166(20):2217-21.
61. Stowe J, Andrew N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009; 169(3):382-8. Epub 24 nov. 2008. Voir :  http://www.bmj.com/cgi/ijlink?linkType=ABST&journalCode=amjepid&resid=169/3/382
62. Tam CC, O’Brien SJ, Petersen I et al. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS One 2007; 2:e344.
63. Conseil consultatif national de l’immunisation. Thimerosal: updated statement. Relevé des maladies transmissibles au Canada, 2007;33(ACS-6):1-13.
64. Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis 2009; 48:456-61.
65. GlaxoSmithKline. Pandemic 2009 influenza update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix^®). Comm. de presse, 9 nov. 2009. Voir :  http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10127.htm

ANNEXE : Schéma de classement de la méthodologie des études individuelles – Conseil consultatif national de l’immunisation

[Précédente] [Table des matières]